Radius Health Stock

Radius Health Equity

Delisted·Jul 10, 2025

The The Equity of Radius Health (RDUS) as of Aug 12, 2026 is 623.11 M USD. In the previous year, The Equity was 908.18 M USD — a change of -31.39% (lower).

Equity

623.11 MUSD

YoY

-31.39%

Last updated:

In 2026, Radius Health's equity was 623.11 M USD, a -31.39% increase from the 908.18 M USD equity in the previous year.

Access this data via the Eulerpool API

Radius Health Stock analysis

What does Radius Health do? Radius Health Inc. is an American pharmaceutical company specializing in the research, development, and marketing of products in the areas of osteoporosis, cancer therapy, and endocrinology. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. The history of Radius Health Inc. began with the discovery of a new compound called Abaloparatide, which was intended for use in the treatment of osteoporosis. The company initiated a Phase III clinical trial to evaluate the efficacy and tolerability of the medication. In 2016, Abaloparatide was approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Since then, Radius Health Inc. has evolved into a leading company specializing in improving women's health. The company has expanded its activities to include oncology and endocrinology and relies on innovative technologies and research to provide better treatment options and medications for patients. The business model of Radius Health Inc. is based on the development and marketing of cost-effective and effective products for the treatment of diseases. The company conducts extensive clinical research and strives to develop new drugs and therapies to improve the lives of women. Radius Health Inc. employs an open and agile corporate culture that promotes innovation and prioritizes the needs of patients. The products offered by Radius Health Inc. include a wide range of medications used in the treatment of osteoporosis, breast cancer, and other diseases. Abaloparatide, the company's flagship product, is a recombinant peptide agonist that stimulates bone formation and reduces the risk of fractures in postmenopausal women. Other products include Elacestrant, an investigative drug for the treatment of breast cancer, and RAD1901, a selective estrogen receptor modulator used in the treatment of hormone-dependent cancers. The company is also active in the field of digital health. Radius Health Inc. has developed an augmented reality app that assists doctors and patients in visualizing bone fractures and other conditions. The app is currently being tested in clinical trials and is expected to be widely used in the future. Overall, Radius Health Inc. is known for its innovative research activities and efforts to improve women's health. The company has an experienced and dedicated team of researchers, scientists, and executives working together to create better treatment options for patients. With a strong pipeline of products and a vision for the future of healthcare, Radius Health Inc. is on track to become a leading provider of medical products and services. Radius Health is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Radius Health's Equity

Radius Health's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Radius Health's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Radius Health's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Radius Health's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Radius Health’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Radius Health stock

The Equity of Radius Health is 623.11 M USD in 2026.

The Equity of Radius Health changed from 908.18 M USD to 623.11 M USD, representing a -31.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Radius Health since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Radius Health historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Radius Health

All Key Metrics — Radius Health